{"id":391523,"date":"2014-10-20T00:00:00","date_gmt":"2014-10-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1614-biopharma-shifts-in-the-u-s-rheumatoid-arthritis-market-access-landscape-due-to-oral-kinase-inhibitors-new\/"},"modified":"2026-04-14T10:29:28","modified_gmt":"2026-04-14T10:29:28","slug":"pforus1614-biopharma-shifts-in-the-u-s-rheumatoid-arthritis-market-access-landscape-due-to-oral-kinase-inhibitors-new","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1614-biopharma-shifts-in-the-u-s-rheumatoid-arthritis-market-access-landscape-due-to-oral-kinase-inhibitors-new\/","title":{"rendered":"Shifts in the U.S. Rheumatoid Arthritis Market Access Landscape Due to Oral Kinase Inhibitors, New Biologics, and Biosimilars: Insights from Payers and Physicians | Physician &#038; Payer Forum | US | 2014"},"content":{"rendered":"<p>The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar market. Bristol-Myers Squibb\u2019s selective costimulation modulator Orencia (abatacept), Biogen Idec\/Roche\/Chugai\/Zenyaku Kogyo\u2019s B-cell inhibitor Rituxan (rituximab), and Roche\/Chugai\u2019s interleukin-6 (IL-6) inhibitor Actemra (tocilizumab) largely compete for TNF-refractory patients. Since the launch of an SC formulation of Orencia in 2011, several biologics (Orencia, Janssen\/Merck\/Mitsubishi Tanabe\u2019s Simponi, and Actemra) have become available in both IV and the SC formulations. In November 2012, Pfizer\/Takeda\u2019s oral janus-activated kinase (Jak) inhibitor, Xeljanz (tofacitinib), was approved. Xeljanz\u2019s convenience (twice-daily oral administration) and efficacy profile, which is similar on several key outcome criteria to that of biologics, make it a compelling option for RA patients, although it does possess a black-box warning, as do many biologics, for its risk of serious infection and malignancy. An additional Jak inhibitor, Eli Lilly\/Incyte\u2019s baricitinib, and additional biologics (Novartis\u2019s IL-17 inhibitor secukinumab, Sanofi\/Regeneron\u2019s IL-6 inhibitor sarilumab, and Janssen\/GlaxoSmithKline\u2019s IL-6 inhibitor sirukumab) have the potential to launch over the next few years. Biosimilar versions of AbbVie\/Eisai\u2019s Humira (adalimumab) and Rituxan are expected to launch in 2017. Thus, competition in this market will become increasingly fierce.<\/p>\n","protected":false},"template":"","class_list":["post-391523","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391523\/revisions"}],"predecessor-version":[{"id":577000,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391523\/revisions\/577000"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}